SQSTM1 and plasma cell myeloma: Frassanito et al.'s work on myeloma cell lines and cancer fibroblasts derived from a chemotherapy-resistant patient identified bortezomib as a protective autophagy activator that acts by increasing LC3-II levels and decreasing P62 levels (55).